Illumina, Inc. (ILMN) Stock Analysis
Healthcare · Diagnostics & Research
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include... Read more
TrendMatrix rates Illumina, Inc. (ILMN) as Hold with moderate confidence. The stock trades at $126.20 with +4.6% upside to the $132.06 price target. Overall score: 5.6/10 across 10 analysis dimensions. Reward/risk ratio: 0.4:1.
Passes 3/4 gates (positive momentum, clean insider activity, no SEC red flags). Fails on favorable risk/reward ratio. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Illumina, Inc. (ILMN) as Hold with moderate confidence. Score 5.6/10.
Take-profit target: $132.06 (+4.6% upside). Reward/risk ratio: 0.4:1. Stop-loss: $111.85.
Analyst target reached - limited upside remaining.
Illumina, Inc. trades at a P/E of 23.1 (forward 21.5). TrendMatrix value score: 4.8/10. Verdict: Hold.
28 analysts cover ILMN with a consensus score of 3.7/5. Average price target: $136.
What does Illumina, Inc. do?Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe,...
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.